Congenital Diaphragmatic Hernia: The Neonatologist’s Perspective

Krisa Van Meurs, MD* and Billie Lou Short, MD†

OBJECTIVES
After completing this article, readers should be able to:

1. Delineate the studies used for prenatal diagnosis of congenital diaphragmatic hernia (CDH).
2. Describe prenatal therapies currently being investigated for the treatment of CDH.
3. Delineate the options available for ventilation of the neonate who has CDH.
4. Describe the potential complications that can be experienced by surviving infants who have CDH.

Introduction
During the past 10 years, significant changes have occurred in the diagnosis and management of congenital diaphragmatic hernia (CDH). The unsuspected birth of an infant who has CDH, the emergency transfer to a center where a pediatric surgeon and neonatologist are available, and the rush to the operating room for repair are a memory. Today we frequently provide prenatal counseling to parents of fetuses who are diagnosed as having CDH in utero, and a myriad of antenatal and postnatal therapies are available. Yet, the quest for therapeutic approaches that will optimize survival for the severely affected infant continues. Several new therapies on the horizon offer promise for the future.

Epidemiology
Most diaphragmatic hernias are posterolateral defects of the Bochdalek type, although Morgagni and parasternal hernias do occur. The incidence of CDH ranges from 0.08 to 0.45 per 1,000 births. The explanation for this variation in incidence most likely is underdiagnosis related to early deaths among neonates who are severely affected. Eighty-five percent of defects are left-sided, 13% are right-sided, and 2% are bilateral. Most studies have found an equal representation of genders, although a 1.25 male-to-female ratio was reported in one large population-based study (see Torfs et al in Suggested Reading).

The incidence of anomalies associated with CDH is 20% to 50%. This range is related to differences in both the definition of anomalies and in patient selection, with higher incidences reported in population-based studies (Table). CDH can be seen as an isolated defect, with multiple other anomalies, as a recognizable nonchromosomal syndrome, or as a chromosomal defect (trisomy or nontrisomy). Congenital anomalies are the most common cause of neonatal death (1.7 per 1,000 births), and CDH may account for 4% to 10% of these deaths. Survival of neonates who have CDH in centers using a wide range of therapeutic strategies ranged between 25% and 83% in the 1990s. Of interest, the survival rate varies inversely with the number of infants reported. In general, population-based studies report lower survival (43.5%) than center-based studies. This difference likely represents the “hidden mortality” of infants dying in utero or shortly after birth who never reach tertiary care centers (Fig. 1).

Prenatal Diagnosis
Both prenatal ultrasonography and measurement of maternal serum alpha-fetoprotein (MS-AFP) have been found to be useful in identifying infants who have CDH. MS-AFP levels are obtained routinely during the 18th week of pregnancy, and low levels have been associated with CDH as well as trisomy 18 and 21. Thus, a low MS-AFP concentration should prompt additional diagnostic testing.

Ultrasonography now is considered the gold standard for diagnosing CDH antenatally. Suggestive findings include polyhydramnios, an absent or intrathoracic stomach bubble, and mediastinal and cardiac shift away from the side of the hernia. The differential diagnosis includes congenital cystic adenomatoid malformation, cystic teratoma, extrapulmonary sequestration, bronchogenic cysts, and neurogenic tumors.

Prenatal Counseling and Evaluation
Once CDH has been diagnosed antenatally by ultrasonography, it is important to define if the defect is isolated or associated with other anomalies known to affect outcome. Level 2 ultrasonography to screen for other anatomic abnormalities should be performed, and amniocentesis should be considered to identify chromosomal abnormalities. After this evaluation, the medical team must present the various man-

ABBREVIATIONS
CDH: congenital diaphragmatic hernia
ECMO: extracorporeal membrane oxygenation
HFOV: high-frequency oscillatory ventilation
INO: inhaled nitric oxide
ITPV: intratracheal pulmonary ventilation
MS-AFP: maternal serum alpha-fetoprotein
PLUG: Plug the Lung Until it Grows
PLV: partial liquid ventilation
SP-A: surfactant apoprotein A
management options to the parents, which generally include pregnancy termination or delivery at a tertiary level center that has multimodality support available. The option of pregnancy termination depends on the gestational age at the time of diagnosis. Fetal surgery now is available to selected infants diagnosed prenatally as an experimental procedure at a few research centers.

**Prenatal Therapies**

Several medical and surgical therapeutic options are available for the fetus diagnosed as having CDH. Studies have indicated that surfactant deficiency may contribute to the pathophysiology of CDH. Autopsy specimens from term infants who had CDH have demonstrated a decrease in the surfactant apoprotein (SP-A) content of alveolar type II cells. Postnatal surfactant therapy has been used in infants who had CDH, but it has not provided long-term benefit. Antenatal glucocorticoid therapy has improved pulmonary maturity and increased oxygenation and pulmonary compliance in an animal model. A multicenter randomized trial of antenatal glucocorticoid administration to mothers of infants who have CDH is needed.

In utero treatment for CDH is being studied at a small number of research centers. A prospective clinical trial of fetuses that had CDH with the liver below the diaphragm documented similarly good survival among those who underwent fetal surgery and those who received conventional treatment. Thus, the risks of fetal surgery in this population appear to be unnecessary. Livers herniated into the chest were found to be impossible to repair in utero because of kinking of the umbilical vein.

Fetal intervention currently is focused on temporary occlusion of the fetal trachea or “PLUG” (Plug the Lung Until it Grows) for those fetuses who have CDH and liver herniation above the diaphragm. Tracheal occlusion has been shown to reverse pulmonary hypoplasia in animal models of CDH. Less invasive approaches to the fetus have evolved to include a video-fetoscopic, intrauterine technique of tracheal occlusion termed “Fetendo-PLUG” that has been associated with encouraging results. The EXIT (EX utero Intrapartum Treatment) procedure has been developed to allow for unplugging of the trachea.

**TABLE 1. Recent Population-based Studies of Congenital Diaphragmatic Hernia (CDH)**

<table>
<thead>
<tr>
<th>VARIABLE</th>
<th>TORF ET AL</th>
<th>WENSTROM ET AL</th>
<th>STEINHORN ET AL</th>
<th>LANGHAM</th>
</tr>
</thead>
<tbody>
<tr>
<td>State</td>
<td>California</td>
<td>Iowa</td>
<td>Minnesota</td>
<td>Florida</td>
</tr>
<tr>
<td>Birth population</td>
<td>718,208</td>
<td>241,473</td>
<td>133,162</td>
<td>962,516</td>
</tr>
<tr>
<td>Number of cases of CDH</td>
<td>237</td>
<td>65</td>
<td>48</td>
<td>166*</td>
</tr>
<tr>
<td>Incidence</td>
<td>0.33/1,000</td>
<td>0.27/1,000</td>
<td>0.36/1,000</td>
<td>0.17/1,000</td>
</tr>
<tr>
<td>Morgagni</td>
<td>5 (2%)</td>
<td>1 (1.5%)</td>
<td>0</td>
<td>Excluded</td>
</tr>
<tr>
<td>Other</td>
<td>5 (2%)</td>
<td>4 (6.5%)</td>
<td>0</td>
<td>Excluded</td>
</tr>
<tr>
<td>Posterolateral</td>
<td>227 (96%)</td>
<td>60 (92%)</td>
<td>48 (100%)</td>
<td>166 (100%)</td>
</tr>
<tr>
<td>Isolated</td>
<td>129 (54%)</td>
<td>47 (72%)</td>
<td>29 (69%)</td>
<td>48/59 (81%)</td>
</tr>
<tr>
<td>MCA + SYN</td>
<td>86 (36%)</td>
<td>14 (22%)</td>
<td>9 (21%)</td>
<td>9/59 (15%)</td>
</tr>
<tr>
<td>Trisomies</td>
<td>10 (4%)</td>
<td>4 (6%)</td>
<td>2 (5%)</td>
<td>1/59 (2%)</td>
</tr>
<tr>
<td>CHR</td>
<td>2 (5%)</td>
<td>0</td>
<td>2 (5%)</td>
<td>1/59 (2%)</td>
</tr>
<tr>
<td>Right:left:bilateral</td>
<td>27:173:5</td>
<td>8:47:0</td>
<td>6:42:1</td>
<td></td>
</tr>
<tr>
<td>Mean gestational age at birth</td>
<td>38.0 wk</td>
<td>—</td>
<td>37±3 wk</td>
<td>37±4 wk</td>
</tr>
<tr>
<td>Male/female ratio</td>
<td>1.25</td>
<td>“No difference”</td>
<td>0.92</td>
<td>1.03</td>
</tr>
<tr>
<td>Birthweight (g)</td>
<td>2,955</td>
<td>—</td>
<td>2,726±703</td>
<td>2,720±865</td>
</tr>
<tr>
<td>Apgar score 1 min</td>
<td>—</td>
<td>—</td>
<td>4±3</td>
<td>—</td>
</tr>
<tr>
<td>Apgar score 5 min</td>
<td>—</td>
<td>—</td>
<td>5±2</td>
<td>—</td>
</tr>
</tbody>
</table>

In this table, MCA = multiple anomalies and nonchromosomal syndromes; CHR = nontrisomy chromosomal defects.

at birth, using the placenta for support until the airway is secured.

Standard postnatal therapy, open fetal tracheal occlusion, and fetoscopic tracheal occlusion in affected fetuses who had “poor prognoses” based on liver herniation were compared recently. The diagnosis of CDH was made prior to 25 weeks’ gestation, and infants had low lung-to-head ratios, a measure indicative of significant pulmonary hypoplasia and high mortality. The survival rates were 38% in the standard therapy group, 15% in the open tracheal occlusion group, and 75% in the Fetendo-PLUG group. The number of maternal complications, such as pulmonary edema, chorioamniotic separation, premature rupture of membranes, and premature labor, appeared to be fewer in the Fetendo-PLUG group compared with the open tracheal occlusion group.

Delivery Room and Immediate Intensive Care

Antenatal diagnosis of CDH has allowed optimal immediate care of affected infants. Parents can be educated about the diagnosis and potential treatment modalities, and the delivery of medical and surgical care can be coordinated by perinatology, neonatology, and pediatric surgical services. Birth at a tertiary care center that has pediatric surgery and neonatology services as well as advanced therapies is desirable. Prompt intubation, avoidance of bag-mask ventilation, placement of a nasogastric tube to provide intestinal decompression, and ongoing care in an intensive care nursery by individuals experienced in the management of the newborn who has CDH now is the norm.

Preoperative Stabilization and Delayed Repair

Emergency surgery was the standard approach to CDH during the 1980s because it was believed that reduction of the hernia would lead to improvement in the respiratory status by allowing the lung to re-expand. With the discovery that the lung was hypoplastic, not atelectatic, and that abnormal arteriolar muscularization and resulting pulmonary hypertension were important in the pathophysiology of CDH, delayed surgical repair was introduced. Miyaska et al first reported two infants who had CDH repair delayed for 24 hours based on the rationale that the risk of pulmonary hypertension might be decreased. In 1986, Cartlidge et al concluded that the use of preoperative stabilization in 17 patients was responsible for a decrease in mortality from 88% to 47%. Sakai et al demonstrated that lung compliance often deteriorates markedly after repair (Figs. 2 and 3).
3). This decrease in lung compliance was attributed to changes in the mechanical forces occurring across the diaphragm after surgery. Sakai also speculated that the pulmonary vasculature may become less reactive with time if the precipitating factors for pulmonary hypertension could be avoided. Currently, most infants who have CDH are stabilized before operative intervention. The mean age at the time of surgery for infants not treated with extracorporeal membrane oxygenation (ECMO) is 73 hours (range, 0 to 443 h).

**Ventilation Strategies**

**CONVENTIONAL MECHANICAL VENTILATION**

Attempts should be made to prevent conditions known to raise pulmonary vascular resistance (hypoxemia, acidosis, hypotension, and hypercarbia). Ventilation with low peak inspiratory pressures is desirable because contralateral pneumothorax can result in added cardiorespiratory instability and decompensation. Sedation and paralysis often are employed if hypoxia persists despite other medical treatments.

**HIGH-FREQUENCY OSCILLATORY VENTILATION (HFOV)**

HFOV has been shown to reduce the need for ECMO in term infants who have respiratory failure. CDH has been associated with failure of HFOV and the need for ECMO more often than other causes of neonatal respiratory failure (Fig. 4). Paranka et al note that the severity of illness in infants who had CDH when HFOV was initiated affected the response to HFOV. The use of this therapy has continued despite no clear indication of its positive impact on survival.

Several recent articles report on the success of a multimodality approach using a combination of therapies, including delayed surgery, HFOV, inhaled nitric oxide (iNO), low ventilator pressures, permissive hypercapnea, surfactant replacement, and ECMO. These single centers cite survival rates of 80% to 90% with a multimodal approach. Multicenter studies are needed to confirm the efficacy and safety of this approach.

**GENTLE VENTILATION**

Wung et al first described the use of gentle ventilation in infants who had persistent pulmonary hypertension of the newborn. This therapeutic approach also has been applied in the management of infants who have CDH. It is based on the concept that overdistension of the lungs will cause pulmonary hypertension and result in lung injury due to barotrauma. The goal is to maintain preductal saturation at greater than 90% with minimal, but adequate ventilatory support that does not involve the use of paralysis, hyperventilation, or alkalosis. Paco2 levels up to 60 mm Hg are tolerated. If hypoxemia persists, tolazoline or dobutamine is added. ECMO is reserved for infants who fail this management strategy. In one comparison of survival for infants who had CDH during several time periods and employing various therapeutic strategies, the use of gentle ventilation, delayed surgery (mean age at surgery, 100 h), and no chest tube resulted in the highest survival (94%) and a low requirement for ECMO.

**INTRATRACHEAL PULMONARY VENTILATION (ITPV)**

ITPV has been shown to maintain low airway pressures while decreasing ventilated anatomic dead space and increasing carbon dioxide removal in animal models of severe pulmonary hypoplasia. Improvement in postductal Paco2, pH, and minute ventilation has been demonstrated in a sheep model of CDH using ITPV in conjunction with a reverse thrust catheter. There is one report of ITPV use in two infants who had CDH on ECMO. Additional clinical experience will be needed before the


![FIGURE 4. Change in the arterial-to-alveolar oxygen ratio (a/A ratio) over the first 6 hours on HFOV for four diagnostic categories. Points represent mean ± SEM. Each line represents the change in the a/A ratio from 0 hours (just before HFOV) to 6 hours of HFOV for each group in each diagnostic category. *P<0.05, HFOV responders (squares) versus nonresponders (triangles) in each diagnostic category for the indicated time point. RDS = respiratory distress syndrome; MAS = meconium aspiration syndrome; CDH/LH = congenital diaphragmatic hernia/lung hypoplasia. Reprinted with permission from Paranka et al. Pediatrics. 1995;95:400–404.](image)
usefulness of this technique in infants who have CDH is determined.

**ECMO**

Following the successful use of ECMO in infants who had respiratory failure, its use was extended to infants who had CDH and severe hypoxemia. Conclusions about whether ECMO has resulted in increased survival for infants who have CDH vary because survival statistics are being compared across different patient populations that have inherent differences in disease severity. Some authors simply have compared survival before the use of ECMO to a subsequent time period during which ECMO was used. In one of these studies, survival during the pre-ECMO era was 47%, which was not significantly different from the 49% survival rate with ECMO. Another investigation found that the use of ECMO improved the survival rate for the “poor prognosis” infant who has CDH, as defined by Bohn et al (Table 2).

Despite the lack of conclusive evidence that ECMO improves survival, it remains a mainstay of therapy for the infant who has CDH. The CDH Study Group found that 57% of infants reported to the CDH Registry during 1995 and 1996 received ECMO, with a survival rate of 54%.

Criteria for the selection of infants most likely to benefit from ECMO remain imprecise. It has been suggested that it is possible to avoid ECMO in those who have CDH and overwhelming pulmonary hypoplasia by requiring a preductal PaO$_2$ of greater than 100 torr and a PaCO$_2$ of less than 50 torr. However, various criteria used to determine high mortality have not been able to predict survival in an ECMO-treated population, which suggests that ECMO be considered for all infants who have CDH.

Currently, ECMO is used both in the preoperative patient who fails to stabilize with medical management and in the postoperative patient who deteriorates after repair. It is clear that infants who have CDH and require ECMO preoperatively have more severe pulmonary hypoplasia and pulmonary hypertension and, thus, lower survival rates. The timing of the repair on or following ECMO remains controversial. The CDH Study Group reported that 33% of infants receiving ECMO were repaired on bypass. The risks of operating on ECMO (bleeding) must be weighed against the risks of operative repair after ECMO decannulation (recurrence of pulmonary hypertension). Two studies have concluded that mortality and morbidity are lower if the repair is undertaken after decannulation from ECMO.

**Surfactant Replacement**

Respiratory failure in the infant who has CDH may be related at least partially to developmental abnormalities of the lung that result in deficiency of surfactant. Postmortem studies have shown decreased expression of SP-A most dramatically on the side of the hernia, suggesting a delay in functional maturation or development of SP-A synthesis. Amniotic fluid analysis of fetuses who have CDH have shown conflicting results. Surfactant replacement in affected infants after birth has been associated with poor results unless the surfactant is administered prior to the first breath (prophylactically) instead of as a rescue. Several authors reporting increased survival rates include surfactant treatment as part of their management strategy.

**Inhaled Nitric Oxide (iNO)**

iNO has been shown in several large randomized clinical trials of infants who have hypoxic respiratory failure to improve oxygenation significantly and decrease the need for ECMO. However, the response to iNO has been suggested to be disease-specific; infants who have CDH experience little improvement with iNO therapy. A later randomized clinical trial of iNO in infants who had CDH by the Neonatal iNOS Group found little improvement in oxygenation and no decrease either in the need for ECMO or in mortality (Table 3). Lack of improvement in oxygenation with iNO use prior to ECMO or CDH repair has been documented. However, significant improvement in oxygenation may occur when iNO follows ECMO and CDH repair. In an animal model of CDH, iNO improved oxygenation.

### TABLE 2. Comparison of Survival Rates by Quadrant in CDH Patients Treated Conventionally (Bohn) and With ECMO (CNMC)

<table>
<thead>
<tr>
<th>Quadrant</th>
<th>Bohn survival rate*</th>
<th>CNMC survival rate</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No.</td>
<td>%</td>
<td>No.</td>
</tr>
<tr>
<td>Preoperative</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quadrant A</td>
<td>3/11</td>
<td>27</td>
<td>3/4</td>
</tr>
<tr>
<td>Quadrant B</td>
<td>23/27</td>
<td>85</td>
<td>9/10</td>
</tr>
<tr>
<td>Quadrant C</td>
<td>0/13</td>
<td>0</td>
<td>6/7</td>
</tr>
<tr>
<td>Quadrant D</td>
<td>3/7</td>
<td>43</td>
<td>2/5</td>
</tr>
<tr>
<td>Postoperative</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quadrant A</td>
<td>4/13</td>
<td>30</td>
<td>1/1</td>
</tr>
<tr>
<td>Quadrant B</td>
<td>27/27</td>
<td>100</td>
<td>9/10</td>
</tr>
<tr>
<td>Quadrant C</td>
<td>0/12</td>
<td>0</td>
<td>6/9</td>
</tr>
<tr>
<td>Quadrant D</td>
<td>1/2</td>
<td>50</td>
<td>4/6</td>
</tr>
</tbody>
</table>


**NS,** Not significant.
and decreased pulmonary artery pressure in combination with either surfactant or partial liquid ventilation. The explanation for the differences in response may reflect the inability of this therapy to act effectively if it is not delivered to the terminal lung unit. Both surfactant and partial liquid ventilation as well as administration of iNO following CDH repair and ECMO may allow iNO to be delivered to terminal lung units, thereby improving ventilation perfusion matching.

Partial Liquid Ventilation (PLV)

PLV may have an important role in the management of infants who have CDH. Perfluorocarbon is instilled into the trachea to a physiologic functional residual capacity, and gas ventilation techniques are continued. PLV has been shown to be effective in recruiting and stabilizing noncompliant alveoli, resulting in a significantly increased PaO₂ and pulmonary compliance in infants who have CDH and are receiving ECMO. iNO has been used in conjunction with PLV in an animal model of CDH, and a significant increase in oxygenation and reduction in pulmonary hypertension over PLV alone was observed. Animal studies also have shown that lung growth was stimulated by continuous intrapulmonary distension with perfluorocarbon for a 21-day period, resulting in increased total alveolar number and total alveolar surface area (Fig. 5).

<table>
<thead>
<tr>
<th>TABLE 3. Primary Outcome of CDH</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Death ≤120 days ECMO</strong></td>
</tr>
<tr>
<td><strong>CONTROL (n = 28)</strong></td>
</tr>
<tr>
<td><strong>TREATMENT GROUP (INO) (n = 25)</strong></td>
</tr>
<tr>
<td>Died</td>
</tr>
<tr>
<td>12 (42.9)</td>
</tr>
<tr>
<td>12 (48.0)</td>
</tr>
<tr>
<td>Received ECMO</td>
</tr>
<tr>
<td>15 (53.6)*</td>
</tr>
<tr>
<td>No. died with ECMO</td>
</tr>
<tr>
<td>4</td>
</tr>
<tr>
<td>8</td>
</tr>
<tr>
<td>No. died without ECMO</td>
</tr>
<tr>
<td>8</td>
</tr>
<tr>
<td>4</td>
</tr>
<tr>
<td>If received ECMO (±SD)</td>
</tr>
<tr>
<td>Age initiated (days)</td>
</tr>
<tr>
<td>0.7 (0.9)</td>
</tr>
<tr>
<td>1.3 (1.9)</td>
</tr>
<tr>
<td>Hours after randomization</td>
</tr>
<tr>
<td>7.1 (6.5)</td>
</tr>
<tr>
<td>10.0 (10.5)</td>
</tr>
</tbody>
</table>

Data expressed as n (%) unless otherwise indicated.
*P = 0.043. Reprinted with permission from NINOS. *Pediatrics. 1997;97:838–845.*

Lung Transplantation

As experience with lung transplantation in adults increased, single lung transplantation for CDH became a theoretical option. To date there has been a single case report of successful lung transplantation in a newborn who had CDH following ECMO. At the age of 5 years, the transplanted lung was removed after the side effects of immunosuppression (growth failure, infection, hirsutism, and hypertension) became increasingly problematic. Balloon occlusion of the pulmonary artery to the transplanted lung during cardiac catheterization demonstrated that pneumonectomy would be tolerated. Patient selection, donor lung size, availability, and the long-term risks of immunosuppression remain barriers to the wider use of lung transplantation in the patient who has CDH.

Outcome

SURVIVAL

Data from the CDH Study Group on 461 patients from 62 centers during 1995 and 1996 report a 63% survival for infants who have CDH. This is the best survival information on aggregate data from multiple centers and is similar to those from other similar studies. As noted previously, these data are not population-based and do not include infants dying in utero or prior to transfer to referral centers.

CDH survivors have a number of significant medical issues after hospital discharge, including chronic lung disease, gastroesophageal reflux, growth failure, reherniation, volvulus, scoliosis, sensorineural hearing loss, and developmental delay.

LUNG FUNCTION AND CHRONIC LUNG DISEASE

Studies of lung function following repair of CDH have conflicting...
results. Numerous investigators have examined lung function by measuring parameters such as total lung capacity, residual volume, and vital capacity. The results have ranged from mildly reduced values to values somewhat higher than expected. The hypoplastic lung may expand to fill the hemithorax, causing the alveoli to become overdistended. Lungs grow rapidly during the first year of life, which minimizes the effect of the initial lung hypoplasia. An autopsy performed on a 5-year-old child who had CDH and died from a fall found approximately normal lung volumes, but fewer and larger alveoli in the ipsilateral lung. The contralateral lung had twice as many alveoli. In addition, fewer bronchial generations were seen in the ipsilateral lung.

Forced expiratory volume during 1 second (FEV1) has been reported to be either normal or mildly decreased. Several authors suggested that these findings represent a pre-emphysematous state. Almost all older CDH survivors are asymptomatic, demonstrating the great reserve capacity of the lung. Whether these differences in lung function represent variations in severity between individual patients or differences in operative results is unclear. Ventilation perfusion scans performed on CDH survivors consistently have shown a persistent reduction in pulmonary blood flow to the hernia side, suggesting a primary vascular pulmonary hypoplasia.

More recent studies of infants treated with ECMO have shown that only 22% were using oxygen at discharge.

GASTROESOPHAGEAL REFLUX
Stolar et al were the first to report on anatomical and functional esophageal abnormalities in infants who survived with CDH. Seventeen of 25 (68%) infants had an air- or fluid-filled mediastinal mass confirmed by upper gastrointestinal series to be ectatic esophagus. Gastroesophageal reflux was diagnosed in 68% using pH probe studies. Many series have confirmed the high incidence of gastroesophageal reflux in those who have CDH. A history of polyhydramnios was found in many of these infants. Foregut obstruction is associated with polyhydramnios because of interference with fetal swallowing. The potential mechanisms responsible for the development of gastroesophageal reflux include esophageal obstruction with impaired esophageal motility, shortening of the esophageal length, disruption in the angle of His by the intrathoracic position of the stomach in utero, and the complete or partial absence of the parahiliatal diaphragm. The majority of infants were treated medically, with surgical intervention required in only 9.6% to 14.8%.

FAILURE TO THRIVE
A high proportion of infants who have CDH remain below the 5th percentile for weight despite the frequent use of nasogastric and gastrostomy tube feedings. Poor growth appears to be related to gastroesophageal reflux rather than chronic lung disease.

REHERNIATION
The incidence of reherniation is increased with the use of synthetic patch repairs and ranges from 5% to 80%. The timing of the reherniation appears to vary. Symptoms occurring with reherniation are usually respiratory, such as coughing and wheezing, or feeding difficulties.

VOLVULUS
Patients who have CDH have malrotation, and a small number will have obstruction of the small bowel due to midgut volvulus or adhesions. If unrecognized, this complication can be life-threatening.

SCOLIOSIS
Chest wall and spinal deformities are found in children and adults who have CDH. A study of 60 adult CDH survivors (mean age, 29 y) documented chest asymmetry in 48%, pectus excavatum in 18%, and significant scoliosis with a Cobb angle of at least 10 degrees in 27%. The incidence of these abnormalities was greatest among those who had a large diaphragmatic defect and those who had undergone thoracotomy versus laparotomy. It is likely that repair of a large defect causes tension, which may interfere with normal development of the thoracic cage and promote asymmetry. Other authors have noted lower incidences of chest wall and spinal deformities, but these reports have had shorter periods of follow-up. Clearly, CDH survivors should be monitored for these abnormalities.

HEARING LOSS
Risk factors for hearing impairment in the newborn population include low birthweight, use of ototoxic medications such as aminoglycosides and furosemide, hyperbilirubinemia, congenital infections, meningitis, and hyperventilation.

Hyperventilation with the induction of a respiratory alkalosis has been associated with the development of a progressive high-frequency sensorineural hearing loss. One study documented hearing loss in 52.5% of infants who had persistent pulmonary hypertension that was associated with exposure to high pH levels and long periods of ventilation. The reported incidence of hearing loss in ECMO survivors has ranged from 4% to 28%. A recent study of hearing in CDH survivors treated with and without ECMO found almost 60% to have sensorineural hearing loss. This hearing loss is progressive, and normal results on a hearing screen at discharge do not preclude the development of later hearing loss. Regular hearing screening is a necessity for CDH survivors.

DEVELOPMENTAL OUTCOME
Limited information is available about the long-term neurodevelopmental outcome of CDH survivors. In general, reports have focused on the outcome of those treated with ECMO. In one group of ECMO-treated CDH survivors between the ages of 8 months and 5 years, 47% of infants had normal scores on Bayley Scales or Stanford-Binet; none scored below 70. Seventeen of 18 children had abnormalities on neuroimaging, but only three had major abnormalities. None had seizure disorders requiring ongoing treatment. The authors concluded that the neurodevelopmental outcome for infants who have CDH is not dissimilar from that of other children treated with ECMO.
Another report of 14 CDH survivors during the first year of life showed lower Bayley scores and a higher incidence of hypotonia when compared with other ECMO survivors. Infants who have CDH have been shown in numerous studies to have longer periods of hospitalization and higher rates of chronic lung disease, both of which affect development. Longer-term follow-up of larger groups of ECMO- and non-ECMO-treated CDH survivors is needed.

Summary
Despite several decades of investigation and a vast array of new therapeutic approaches, the optimal therapeutic strategy for the newborn who has CDH remains undetermined. Ongoing data collection and the development of multicenter clinical trials should clarify which therapies are most likely to be of benefit.

SUGGESTED READING


Congenital Diaphragmatic Hernia: The Neonatologist's Perspective
Krisa Van Meurs and Billie Lou Short
Pediatrics in Review 1999;20;e79
DOI: 10.1542/pir.20-10-e79

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://pedsinreview.aappublications.org/content/20/10/e79